Adcendo ApS to Present Data on its Novel ADC Target uPARAP in Glioblastoma Multiforme at the American Association for Cancer Research Annual Meeting 2024

Adcendo California

Data demonstrate that uPARAP is highly expressed in tumor samples obtained from glioblastoma multiforme patientsuPARAP targeting ADC shows cytotoxicity in glioblastoma multiforme cancer cells in vitro and exhibits potent in vivo anti-tumor activity in a glioblastoma multiforme PDX modelData provides evidence that uPARAP targeting ADCs are a potential novel treatment option for glioblastoma multiforme patientsView original content:https://www.prnewswire.co.uk/news-releases/adcendo-aps-to-present-data-on-its-novel-adc-target-uparap-in-glioblastoma-multiforme-at-the-american-association-for-cancer-research-annual-meeting-2024-302107562.html